Crescent Biopharma Inc Stock Price, News & Analysis

Catalyst Biosciences (NASDAQ: CBIO) has announced an underwritten public offering of its common stock, with market conditions influencing the amount and terms. The company may grant underwriters a 30-day option to purchase an additional 15% of shares. Proceeds will support general corporate purposes, including research and development in hemophilia and complement programs, capital expenditures, and operational costs. The offering will use a previously filed effective registration statement. Piper Sandler & Co. and Raymond James & Associates are involved as bookrunners.

Catalyst Biosciences (NASDAQ: CBIO) announced two e-poster presentations at the EAHAD Virtual Congress occurring from February 3-5, 2021. The posters highlight the effectiveness of Marzeptacog Alfa (Activated) for treating spontaneous bleeding in both hemophilia A rats and dogs. Presenters include Tom Knudsen and Howard Levy, with accessible materials post-event on the Catalyst website.

Additionally, Catalyst is focused on developing solutions for rare coagulation disorders and has a partnership with Biogen for complement-related therapies.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced participation in a fireside chat hosted by LifeSci Capital on January 19, 2021, at 1:00 pm ET. Management will discuss new complement programs and developments surrounding CB 2782, a C3 degrader partnered with Biogen, and MarzAA, a late-stage asset for hemostasis. The call registration can be accessed via email, with a replay available on the company's website for 90 days. Catalyst focuses on rare disorders of the complement and coagulation systems, boasting two late-stage clinical programs, including MarzAA.

Catalyst Biosciences (NASDAQ: CBIO) presented its Phase 3 study, Crimson 1, at the ASH meeting on December 7, 2020. The study evaluates Marzeptacog alfa (activated), a subcutaneous therapy for treating bleeding in patients with Hemophilia A or B with inhibitors. It aims to demonstrate non-inferiority compared to Standard of Care, enrolling about 60 subjects and treating 244 bleeding episodes. The primary endpoint is effective hemostasis at 24 hours. CEO Nassim Usman stated that MarzAA could be a significant addition to hemophilia treatment options.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) will host a research and development call on December 14, 2020, at 12:00 pm ET regarding its systemic complement regulator programs. Management will introduce their first subcutaneously-dosed systemic complement candidate and provide insights on their protease engineering platform that targets various diseases. The call will feature Ronald P. Taylor, Ph.D., who will discuss complement-related diseases. This information will be available on their website for 90 days.

Catalyst Biosciences has received FDA Fast Track Designation for Marzeptacog alfa (MarzAA), an innovative subcutaneous treatment for episodic bleeding in Hemophilia A or B patients with inhibitors. The designation aims to expedite development for addressing unmet medical needs. A pivotal Phase 3 study, CRIMSON 1, will begin this month, assessing MarzAA's safety and efficacy compared to Standard of Care. The trial aims to enroll 60 subjects, aiming for effective hemostasis in treated bleeding episodes. This designation may enhance MarzAA's market accessibility and importance in hemophilia treatment.

Catalyst Biosciences (NASDAQ: CBIO) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A pre-recorded presentation will be accessible for registered attendees and on the company's website for 90 days. The company will also engage in 1x1 meetings with investors. Catalyst focuses on addressing unmet needs in rare hematologic and complement-mediated disorders, advancing therapies including MarzAA and DalcA for hemophilia. The company emphasizes ongoing collaborations and potential risks surrounding its pipeline.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced a poster presentation on Marzeptacog alfa (activated) or MarzAA at the 62nd Annual American Society of Hematology meeting, scheduled for December 5-8, 2020. The presentation will cover the Phase 3 Crimson 1 Study, which evaluates MarzAA for treating bleeding episodes in patients with Hemophilia A and B with inhibitors. The first patient is set to be dosed by late 2020. MarzAA represents the only subcutaneous bypass agent in development for these conditions. Catalyst focuses on rare hematologic disorders, with multiple clinical programs underway.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) reported its third-quarter results for 2020, ending September 30. The net loss was $16 million, equating to ($0.73) per share, an improvement from a loss of $12.7 million or ($1.06) per share in Q3 2019. The company is advancing clinical trials for its MarzAA product and expects to enroll patients in a Phase 3 study for hemophilia treatment by year-end. Cash and investments totaled $104.1 million. Additionally, Catalyst secured a patent for its complement program, providing protection until at least 2038.